Resolian provides qPCR services at its US and Chongqing sites, supporting gene expression and biodistribution studies. The executive leadership team, boasting over 20 years of collective experience in the Cell and Gene Therapy (CGT) and Vaccine fields, ensures a wealth of expertise guiding these services.
Excitingly, as our team expands molecular offerings to our sites in the UK and Australia, Resolian will enhance capabilities by incorporating ddPCR (droplet digital PCR).
This expansion reflects Resolian’s commitment to continually advancing and diversifying these molecular services to contribute to the progress of scientific research in these regions, and meet your evolving needs.
Reach out to us directly to learn more about Resolian’s PCR services.